Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer

Sakakibara-Konishi, Jun; Oizumi, Satoshi; Kinoshita, Ichiro; Shinagawa, Naofumi; Kikuchi, Junko; Kato, Mototsugu; Inoue, Tetsuya; Katoh, Norio; Onimaru, Rikiya; Shirato, Hiroki; Dosaka-Akita, Hirotoshi; Nishimura, Masaharu

Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer

Sakakibara-Konishi, Jun; Oizumi, Satoshi; Kinoshita, Ichiro et al.

Lung Cancer, 2011, 74(2), 248-252

Permalink : https://hdl.handle.net/2115/47868

このアイテムのアクセス数:1,451件（2026-08-12 02:56 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
LC74-2_248-252	pdf	302 KB	1,909

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/47868
タイトル	Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer
著者	Sakakibara-Konishi, Jun ; Oizumi, Satoshi ; Kinoshita, Ichiro ; Shinagawa, Naofumi ; Kikuchi, Junko ; Kato, Mototsugu ; Inoue, Tetsuya ; Katoh, Norio ; Onimaru, Rikiya ; Shirato, Hiroki ; Dosaka-Akita, Hirotoshi ; Nishimura, Masaharu
e-Rad_Researcher 50374278 著者名 Sakakibara-Konishi, Jun
e-Rad_Researcher 10421968 著者名 Oizumi, Satoshi
e-Rad_Researcher 40343008 著者名 Kinoshita, Ichiro
e-Rad_Researcher 20431372 著者名 Shinagawa, Naofumi
著者名 Kikuchi, Junko
e-Rad_Researcher 60271673 著者名 Kato, Mototsugu
e-Rad_Researcher 10431363 著者名 Inoue, Tetsuya
e-Rad_Researcher 80572495 著者名 Katoh, Norio
e-Rad_Researcher 80374461 著者名 Onimaru, Rikiya
e-Rad_Researcher 20187537 著者名 Shirato, Hiroki
e-Rad_Researcher 70222528 著者名 Dosaka-Akita, Hirotoshi
e-Rad_Researcher 00208224 著者名 Nishimura, Masaharu
言語	英語
キーワード	Phase I study
	Non-small cell lung cancer
	Chemotherapy
	Paclitaxel
	Carboplatin
	Radiation
発行日	2011-11
出版者	Elsevier Ireland
収録物名	Lung Cancer
巻(号)	74(2)
ページ	248-252
抄録	Introduction: Although paclitaxel with carboplatin and thoracic radiotherapy has improved survival for patients with locally advanced unresectable non-small cell lung cancer (NSCLC), the optimal dose of paclitaxel has not been well defined in Japan. This study was conducted to determine the maximum tolerated dose (MTD) and recommended dose (RD) of paclitaxel in combination with carboplatin and concurrent real-time tumor-tracking thoracic radiation therapy (thoracic RTRT). Patients and methods: Previously untreated patients with histologically confirmed, locally advanced unresectable NSCLC were eligible. Before treatment, gold markers were inserted into the lung and the mediastinum of all patients. RTRT comprised a total of 66 Gy at 2 Gy/fraction, 5 days/week, for 7 weeks. Patients received paclitaxel at a starting dose of 40 mg/m2 followed by carboplatin at a fixed area under the curve (AUC) of 2, as a weekly regimen with RTRT. The dose of paclitaxel was escalated by 5 mg/m2 per level. Results: Eight patients with locally advanced unresectable NSCLC were enrolled and treated with two dose levels of paclitaxel (40 mg/m2 and 45 mg/m2), carboplatin (AUC = 2) and RTRT. No dose limiting toxicities (DLTs) were observed at Level 1 (paclitaxel, 40 mg/m2 and carboplatin, AUC = 2). At Level 2 (paclitaxel, 45 mg/m2 and carboplatin, AUC = 2), two of five patients experienced DLTs, in the form of esophagitis and discontinuation of chemotherapy more than twice. The MTD and RD of paclitaxel were thus defined as 45 mg/m2 and 40 mg/m2, respectively. Conclusions: This phase I study was well tolerated and the RD of paclitaxel and carboplatin with RTRT is 40 mg/m2 at AUC = 2, respectively. Further studies are warranted to evaluate the efficacy of this regimen.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
PISSN	0169-5002
関連情報	PMID 21397973
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.lungcan.2011.02.009